Gust H. Bardy

Gust H. Bardy

Auto-generated profile, based on publicly available information

Gust H. Bardy

Seattle Institute for Cardiac Research, University of Washington, Seattle, WA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2005 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
GBGust H. Bardy
Gust H. Bardy
KLKerry L. Lee
Kerry L. Lee
DMDaniel B. Mark
Daniel B. Mark
JPJeanne E. Poole
Jeanne E. Poole
DPDouglas L. Packer
Douglas L. Packer
JIJohn H. Ip
John H. Ip
Sudden death from cardiac causes remains a leading cause of death among patients with congestive heart failure (CHF). Treatment with amiodarone or an implantable cardioverter–defibrillator (ICD) has been proposed to improve the prognosis in such patients. We randomly assigned 2521 patients with New York Heart Association (NYHA) class II or III CHF and a left ventricular ejection fraction (LVEF) of 35 percent or less to conventional therapy for CHF plus placebo (847 patients), conventional therapy plus amiodarone (845 patients), or conventional therapy plus a conservatively programmed, shock-only, single-lead ICD (829 patients). Placebo and amiodarone were administered in a double-blind fashion. The primary end point was death from any cause. The median LVEF in patients was 25 percent; 70 percent were in NYHA class II, and 30 percent were in class III CHF. The cause of CHF was ischemic in 52 percent and nonischemic in 48 percent. The median follow-up was 45.5 months. There were 244 deaths (29 percent) in the placebo group, 240 (28 percent) in the amiodarone group, and 182 (22 percent) in the ICD group. As compared with placebo, amiodarone was associated with a similar risk of death (hazard ratio, 1.06; 97.5 percent confidence interval, 0.86 to 1.30; P=0.53) and ICD therapy was associated with a decreased risk of death of 23 percent (0.77; 97.5 percent confidence interval, 0.62 to 0.96; P=0.007) and an absolute decrease in mortality of 7.2 percentage points after five years in the overall population. Results did not vary according to either ischemic or nonischemic causes of CHF, but they did vary according to the NYHA class. In patients with NYHA class II or III CHF and LVEF of 35 percent or less, amiodarone has no favorable effect on survival, whereas single-lead, shock-only ICD therapy reduces overall mortality by 23 percent.

1 July 2010 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
GBGust H. Bardy
Gust H. Bardy
WSWarren M. Smith
Warren M. Smith
MHMargaret A. Hood
Margaret A. Hood
ICIan G. Crozier
Ian G. Crozier
IMIain C. Melton
Iain C. Melton
AGAndrew A. Grace
Andrew A. Grace
Implantable cardioverter–defibrillators (ICDs) prevent sudden death from cardiac causes in selected patients but require the use of transvenous lead systems. To eliminate the need for venous access, we designed and tested an entirely subcutaneous ICD system.

24 April 2008 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
GBGust H. Bardy
Gust H. Bardy
KLKerry L. Lee
Kerry L. Lee
DMDaniel B. Mark
Daniel B. Mark
JPJeanne E. Poole
Jeanne E. Poole
WTWilliam D. Toff
William D. Toff
ESEleanor B. Schron
Eleanor B. Schron
The most common location of out-of-hospital sudden cardiac arrest is the home, a situation in which emergency medical services are challenged to provide timely care. Consequently, home use of an automated external defibrillator (AED) might offer an opportunity to improve survival for patients at risk. We randomly assigned 7001 patients with previous anterior-wall myocardial infarction who were not candidates for an implantable cardioverter–defibrillator to receive one of two responses to sudden cardiac arrest occurring at home: either the control response (calling emergency medical services and performing cardiopulmonary resuscitation [CPR]) or the use of an AED, followed by calling emergency medical services and performing CPR. The primary outcome was death from any cause. The median age of the patients was 62 years; 17% were women. The median follow-up was 37.3 months. Overall, 450 patients died: 228 of 3506 patients (6.5%) in the control group and 222 of 3495 patients (6.4%) in the AED group (hazard ratio, 0.97; 95% confidence interval, 0.81 to 1.17; P=0.77). Mortality did not differ significantly in major prespecified subgroups. Only 160 deaths (35.6%) were considered to be from sudden cardiac arrest from tachyarrhythmia. Of these deaths, 117 occurred at home; 58 at-home events were witnessed. AEDs were used in 32 patients. Of these patients, 14 received an appropriate shock, and 4 survived to hospital discharge. There were no documented inappropriate shocks. For survivors of anterior-wall myocardial infarction who were not candidates for implantation of a cardioverter–defibrillator, access to a home AED did not significantly improve overall survival, as compared with reliance on conventional resuscitation methods. (ClinicalTrials.gov number, NCT00047411.)

1 February 2016 in American Heart Journal
Verified
Journal Article
Closed access
ACAlessandro Capucci
Alessandro Capucci
DADaniela Aschieri
Daniela Aschieri
FGFederico Guerra
Federico Guerra
VPValentina Pelizzoni
Valentina Pelizzoni
SNStefano Nani
Stefano Nani
GBGust H. Bardy
Gust H. Bardy

1 July 1995 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
JPJeanne E. Poole
Jeanne E. Poole
GBGust H. Bardy
Gust H. Bardy
PKPeter J. Kudenchuk
Peter J. Kudenchuk
GDG. Lee Dolack
G. Lee Dolack
MRMerritt H. Raitt
Merritt H. Raitt
GJGeorge Johnson
George Johnson

7 August 2012 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
RCRiccardo Cappato
Riccardo Cappato
SCserenella castelvecchio
serenella castelvecchio
PEPaul Erlinger
Paul Erlinger
RSRick Sanghera
Rick Sanghera
DSDonald Scheck
Donald Scheck
GBGust H. Bardy
Gust H. Bardy